Ізраїль - іврит - Ministry of Health

gsk consumer healthcare, israel ltd - terbinafine - ג'ל - terbinafine 1 % - terbinafine - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidemophyton floccosum. pityriasis ( tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).

Ізраїль - іврит - Ministry of Health

rafa laboratories ltd - terbinafine hydrochloride - קרם - terbinafine hydrochloride 1 % - terbinafine - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.t.rubrum, t. mentagrophytes, t. verrucosu, t. violaceum), microsporum canis and epidemophyton floccosum. yeast infections of the skin, principally those caused by the genus candida (e.g. candida albicans). pityriasis (tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).

Ізраїль - іврит - Ministry of Health

rafa laboratories ltd - terbinafine hydrochloride - קרם - terbinafine hydrochloride 1 % - terbinafine - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidemophyton floccosum. yeast infections of the skin, principally those caused by the genus candida (e.g. candida albicans). pityriasis (tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).

Ізраїль - іврит - Ministry of Health

rafa laboratories ltd - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

Ізраїль - іврит - Ministry of Health

rafa laboratories ltd - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

Ізраїль - іврит - Ministry of Health

merck sharp & dohme israel ltd - alendronic acid as alendronate sodium trihydrate; colecalciferol - טבליה - colecalciferol 140 mcg; alendronic acid as alendronate sodium trihydrate 70 mg - colecalciferol - colecalciferol - fosavance is indicated for : treatment of osteoporosis in postmenopausal women: for the treatment of osteoporosis, fosavance increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). treatment to increase bone mass in men with osteoporosis.

Ізраїль - іврит - Ministry of Health

organon pharma israel ltd., israel - alendronic acid as alendronate sodium trihydrate; colecalciferol - טבליה - colecalciferol 140 mcg; alendronic acid as alendronate sodium trihydrate 70 mg - colecalciferol

Ізраїль - іврит - Ministry of Health

novartis israel ltd - travoprost - תמיסה לעין - travoprost 0.004 %w/v - travoprost - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication.

Ізраїль - іврит - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 10a; pneumococcal polysaccharide serotype 11a; pneumococcal polysaccharide serotype 12f; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 15b; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 22f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 33f; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 8; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 33f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 22f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 15b 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 12f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 11a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 10a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 8 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated

Ізраїль - іврит - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob